163 related articles for article (PubMed ID: 12475293)
1. Synthesis of sildenafil analogues from anacardic acid and their phosphodiesterase-5 inhibition.
Paramashivappa R; Phani Kumar P; Subba Rao PV; Srinivasa Rao A
J Agric Food Chem; 2002 Dec; 50(26):7709-13. PubMed ID: 12475293
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring.
Kim DK; Lee JY; Lee N; Ryu DH; Kim JS; Lee S; Choi JY; Ryu JH; Kim NH; Im GJ; Choi WS; Kim TK
Bioorg Med Chem; 2001 Nov; 9(11):3013-21. PubMed ID: 11597484
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.
Wang Y; Chackalamannil S; Hu Z; Boyle CD; Lankin CM; Xia Y; Xu R; Asberom T; Pissarnitski D; Stamford AW; Greenlee WJ; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2002 Nov; 12(21):3149-52. PubMed ID: 12372521
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and phosphodiesterase 5 inhibitory activity of novel phenyl ring modified sildenafil analogues.
Kim DK; Lee N; Lee JY; Ryu DH; Kim JS; Lee SH; Choi JY; Chang K; Kim YW; Im GJ; Choi WS; Kim TK; Ryu JH; Kim NH; Lee K
Bioorg Med Chem; 2001 Jun; 9(6):1609-16. PubMed ID: 11408180
[TBL] [Abstract][Full Text] [Related]
5. The discovery of novel, potent and selective PDE5 inhibitors.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2001 Sep; 11(18):2461-4. PubMed ID: 11549447
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5(')-sulfonamide moiety of phenyl ring.
Kim DK; Young Lee J; Park HJ; Minh Thai K
Bioorg Med Chem Lett; 2004 May; 14(9):2099-103. PubMed ID: 15080987
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
Manganiello V
Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
[No Abstract] [Full Text] [Related]
8. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
J Med Chem; 2000 Apr; 43(7):1257-63. PubMed ID: 10753463
[TBL] [Abstract][Full Text] [Related]
9. T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs.
Mochida H; Noto T; Inoue H; Yano K; Kikkawa K
Eur J Pharmacol; 2004 Feb; 485(1-3):283-8. PubMed ID: 14757152
[TBL] [Abstract][Full Text] [Related]
10. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
Watanabe H
Intern Med; 2004 Oct; 43(10):891-3. PubMed ID: 15575233
[No Abstract] [Full Text] [Related]
12. [Erectile dysfunction: an update on new therapeutic options].
Roumeguère T
Acta Urol Belg; 2000; 68(2):41-2. PubMed ID: 11098588
[No Abstract] [Full Text] [Related]
13. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.
Gibson A
Eur J Pharmacol; 2001 Jan; 411(1-2):1-10. PubMed ID: 11137852
[TBL] [Abstract][Full Text] [Related]
15. 1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.
Ukita T; Nakamura Y; Kubo A; Yamamoto Y; Moritani Y; Saruta K; Higashijima T; Kotera J; Fujishige K; Takagi M; Kikkawa K; Omori K
Bioorg Med Chem Lett; 2003 Jul; 13(14):2341-5. PubMed ID: 12824030
[TBL] [Abstract][Full Text] [Related]
16. Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism.
Lin G; Xin ZC; Lue TF; Lin CS
J Urol; 2003 Aug; 170(2 Pt 2):S15-8; discussion S19. PubMed ID: 12853767
[TBL] [Abstract][Full Text] [Related]
17. Tachyphylaxis and phosphodiesterase type 5 inhibitors.
Steers WD
J Urol; 2002 Jul; 168(1):207. PubMed ID: 12050542
[No Abstract] [Full Text] [Related]
18. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
Park K; Moreland RB; Goldstein I; Atala A; Traish A
Biochem Biophys Res Commun; 1998 Aug; 249(3):612-7. PubMed ID: 9731184
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta.
Mochida H; Inoue H; Takagi M; Noto T; Yano K; Kikkawa K
Eur J Pharmacol; 2002 Apr; 440(1):45-52. PubMed ID: 11959087
[TBL] [Abstract][Full Text] [Related]
20. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
Hirose R; Okumura H; Yoshimatsu A; Irie J; Onoda Y; Nomoto Y; Takai H; Ohno T; Ichimura M
Eur J Pharmacol; 2001 Nov; 431(1):17-24. PubMed ID: 11716838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
